Previous Article | Next Article ![]()
Journal of Virology, October 2003, p. 10725-10729, Vol. 77, No. 19
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.19.10725-10729.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Innate Immunity Laboratory, National Institute of Agrobiological Sciences, Tsukuba, Ibaraki 305-8634,1 Institute of Agriculture and Forestry, University of Tsukuba, Tsukuba, Ibaraki 305-8572, Japan2
Received 7 March 2003/ Accepted 14 July 2003
|
|
|---|
|
|
|---|
The infection cycle of BmNPV is mediated by two phenotypically different viral particles: the occlusion-derived virus (ODV) and the budded virus (BV) (9). Occlusion bodies consisting of a crystalline matrix of polyhedron proteins contain ODV particles. When the occlusion bodies are ingested by B. mori larvae, they are dissolved by the alkaline gut juice. The enveloped virions are released and then initiate infection in the midgut columnar epithelial cells. In the case of Autographa californica multicapsid nucleopolyhedrovirus, it was shown that a proportion of the parental virus travels through the midgut epithelial layer, possibly utilizing the plasma membrane reticular system, and enters the hemocoel at the same time, infecting the hemocytes (3). In contrast to ODV, the BV particle consists of a single nucleocapsid surrounded by an envelope acquired as it buds from the plasma membrane of an infected cell and spreads beyond the midgut through the tracheae.
Studies on antiviral immunity in insects are still in their infancy, and defense mechanisms at an early stage of viral infection in the alimentary canal remain unknown. The aim of the present study was to determine whether B. mori contains proteins showing anti-BmNPV activity in the gut in order to obtain a clue as to the antiviral mechanisms involved in insect immunity.
A protein showing anti-BmNPV was purified through ammonium sulfate fractionation, gel filtration, and reverse-phase high-performance liquid-column chromatography (HPLC) (Fig. 1A). The protein was eluted with 49.5% acetonitrile-0.05% trifluoroacetic acid (TFA) by reverse-phase HPLC. The homogeneity of the antiviral peak fraction was examined both by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) using a Voyager RP biospectrometry system (PerSeptive Biosystems) and by liquid chromatography-mass spectrometry (LC-MS) using a Series 1100MSD (Hewlett-Packard). The results showed no contamination of this protein fraction (Fig. 1A, inset). The molecular mass of this protein was calculated to be 28,988 Da by MALDI-TOF MS and 28,978 Da by LC-MS. The protein showed strong antiviral activity against ODV of BmNPV (Fig. 1B). All fifth-instar larvae inoculated with ODV (22.5 ng/larva) treated with this protein (2.2 µg/larva) entered the pupal stage, although all control larvae inoculated with nontreated ODV died within 168 h postinfection (hpi) (data not shown).
![]() View larger version (20K): [in a new window] |
FIG. 1. Final HPLC purification profile and antiviral activity of Bmlipase-1. (A) Purification profile of Bmlipase-1. Bmlipase-1 was eluted with 49.5% acetonitrile-0.05% TFA by reverse-phase HPLC. The arrow indicates the Bmlipase-1 position. The inset shows the LC-MS spectrum with molecular mass of Bmlipase-1. B. mori larvae of the Daizo race were reared on mulberry leaves, whereas larvae of the Tokai x Asahi race were fed an artificial diet (Nihonnosanko). The silkworms were maintained in the silkworm rearing room under controlled environmental conditions at 27°C. The digestive juice was collected from B. mori (Daizo race) larvae in an ice-cold tube by mild electric shock, and ammonium sulfate was added to give a 40% saturation. The precipitate was suspended in 40 mM phosphate buffer (pH 7.4) and treated with 50% n-butanol (final concentration) overnight at 4°C, and the lower aqueous layer was collected after centrifugation at 10,000 x g for 30 min. Half-volume ice-cold acetone was added to this solution to precipitate proteins in the aqueous layer. The precipitated proteins were collected by centrifugation at 10,000 x g for 30 min, dried, and dissolved in 40 mM phosphate buffer (pH 7.4). The solution equilibrated with the same buffer was applied to a Superdex 200 HR 10/30 column attached to a fast-performance liquid chromatography system (Pharmacia). Each fraction was tested for antiviral activity. Antiviral fractions were further purified through a reverse-phase column, Sephasil C8 SC 2.1/10, attached to a SMART system (Pharmacia) with a linear gradient of acetonitrile-0.05% TFA. (B) Antiviral activity against BmNPV-ODV. Infectivity was expressed as relative light units/10 µl of hemolymph. The data shown are means ± standard deviations of results from five experiments. The infectivity of BmNPV treated with 2.2 µg of Bmlipase-1 per larva (indicated as ODV + Bmlipase-1) was compared to that of nontreated BmNPV (indicated as ODV). As a negative control, the same amount of hemolymph from nontreated B. mori larvae was used to measure the background levels of luciferase activity (indicated as None). The ODV concentration was22.5 ng/larva. Luciferase activity was measured at 136 hpi. The antiviral activity was assayed using BmNPVp10luc, which contained a luciferase reporter gene driven by the p10 promoter (15). The recombinant BmNPV was a gift from Shuichiro Tomita from our institute. The virus expresses a luciferase reporter gene at 15 hpi. The infection and mortality levels were quantified in the Tokai x Asahi race. The ODV was purified by ultracentrifugation on sucrose gradient (14). The ODV (22.5 ng/larva) suspension was mixed with the purified protein (2.2 µg/larva) and dissolved in 40 mM phosphate buffer (pH 8.0). This mixture was incubated at 30°C for 1 h. Fifth-instar larvae just after ecdysis were orally inoculated with 5 µl of ODV mixture. Thirty larvae were used for each treatment. The hemolymph was collected at various hpi and assayed for luciferase activity. Ten microliters of hemolymph was added to 50 µl of luciferase assay buffer (Promega), and luciferase activity was measured using a Luminocounter 700 (Microtech-Nition).
|
![]() View larger version (53K): [in a new window] |
FIG.2. Nucleotide and deduced amino acid sequences of Bmlipase-1 cDNA. The putative signal sequence of purified Bmlipase-1 is underlined. Boxed amino acid residues denote the active site of the lipase family (10). An asterisk shows the termination codon (TAA). The polyadenylation signal is double-underlined. B. mori EST database (Silkbase; http://www.ab.a.u-tokyo.ac.jp/silkbase/) was screened based on the N-terminal amino acid sequence of the purified protein. A clone (mg809) isolated from the midgut cDNA library showed homology with this protein. The nucleotide sequence of the mg809 clone, kindly provided by Kazuei Mita from our institute, was determined to lack the sequence of the 5' region. Complete nucleotide sequence was obtained by a First Choice RLM-RACE kit (Ambion) using mRNA extracted from the midgut and purified by a Quick Prep mRNA kit (Amersham Pharmacia Biotech). The nucleotide sequence was determined by dye-terminator cycle sequencing using a DNA sequencer (ABI 373A).
|
![]() View larger version (57K): [in a new window] |
FIG. 3. Structural and functional properties of Bmlipase-1. (A) Comparison of the amino acid sequence of Bmlipase-1 with that of D. melanogaster lipase (accession number AE003759-4) (1) and human lipase (6). The amino acid sequence from positions 338 to 500 of human lipase is omitted. Identical amino acid residues are boxed in black. The active site of the lipase family (GXSXG) is shown with asterisks. (B) Lipase activity measurement. The data shown are a typical result of three independent experiments. Lipase activity of both nonpurified digestive juice and Superdex 200 fraction is also shown. As positive and negative controls, Phycomyces nitens lipase (Pnlipase) and bovine serum albumin (BSA) were used, respectively. The protein concentration was determined using a Bio-Rad protein assay kit. Lipase activity was assayed according to the method of Arreguin-Espinosa et al. (2). P. nitens lipase was obtained from Wako. Lipase activity was measured at 560 nm and is expressed per milligram of protein.
|
![]() View larger version (13K): [in a new window] |
FIG. 4. Effect of Bmlipase-1 on BmNPV-ODV infectivity. ODV infectivity was examined after treatment of ODV (860 ng/larva) with different concentrations of Bmlipase-1. Data shown are means ± standard deviations of results from five experiments. Luciferase activity was measured at 136 hpi. Detailed experimental conditions are described in the legend to Fig. 1. Note that luciferase activity of hemolymph samples from nontreated B. mori larvae was also measured to determine the background level, and the level of relative light units (RLU) per 10 µl of hemolymph was 120 ± 3.4.
|
![]() View larger version (57K): [in a new window] |
FIG. 5. Northern blot analysis of Bmlipase-1 gene expression. (A) Bmlipase-1 gene expression in the fat body (F), hemocyte (H), midgut (MG), Malpighian tubule (MP), silk gland (S), and trachea (T). As an internal marker, 28S rRNA is shown in the lower panel. Tissues such as the midgut, hemocyte, silk gland, trachea, fat body, and Malpighian tubule were prepared from two fifth-instar larvae. The midgut was further separated into anterior, middle, and posterior portions. Total RNA from each tissue was isolated with ISOGEN (Nippon Gene). Northern blotting (11) was conducted with 20 µg of RNA and screened with a digoxygenin-labeled Bmlipase-1 probe prepared by PCR DIG labeling mix (Roche). (B) Bmlipase-1 gene expression in the anterior (A), middle (M), and posterior (P) portions of the midgut. (C) Bmlipase-1 gene expression in fourth and fifth instars. Fourth-instar days 5 and 6 are the molting stage. Fifth-instar day 8 is the wandering stage. (D) Effects of BmNPV infection on Bmlipase-1 gene expression. Bmlipase-1 gene expression was analyzed at different time intervals after BmNPV infection.
|
Bmlipase-1 gene regulation is unique. Gene expression of this enzyme is not upregulated by viral infection but seems to be hormonally regulated, suggesting that the main role of the enzyme is food digestion. However, Bmlipase-1 is also involved in primary defense against viral infection to protect B. mori midgut epithelial cells from ODV at the initial infection stage. The antiviral mechanisms of Bmlipase-1 which suppress BmNPV replication remain unclear. A. californica M NPV protein P74 is associated with the ODV envelope. P74 is essential for oral infection with ODV and has been proposed to play a role in midgut attachment and/or fusion (12). It will be interesting to determine if Bmlipase-1 destroys the virion envelope and, as a result, prevents viral attachment to the midgut through a P74 homolog. It remains to be clarified whether Bmlipase-1 inhibits multiplication of other viruses such as cytoplasmic polyhedrosis and densonucleosis viruses that are also pathogenic for B. mori. More proteins are likely involved in primary defense, and understanding the insect immune mechanisms against viral pathogens is important for both the silk industry and general agricultural pest control.
Nucleotide sequence accession number. The nucleotide sequence of Bmlipase-1 has been deposited with the DDBJ, EMBL, and GenBank Data Libraries under accession number AB076385.
This work was supported in part by the Program for Promotion of Basic Research Activities for Innovative Biosciences of the Bio-Oriented Technology Research Advancement Institution in Japan and by Grants-in-Aid (Bio Design Program and Insect Technology Program) from the Ministry of Agriculture, Forestry, and Fisheries of Japan.
|
|
|---|
B factor relish by rapid endoproteolytic cleavage. EMBO J. 1:347-352.[CrossRef]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»